netFormulary

Lancashire and South Cumbria
Formulary

9 Nutrition and blood

This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.

For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/

09-01-03 Drugs used in hypoplastic, haemolytic, and renal anaemias

Iptacopan

Formulary

Iptacopan is recommended, within its anticipated marketing authorisation, as an option for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults with haemolytic anaemia.

Iptacopan will be available via the Innovative Medicines Fund (IMF) according to a set of treatment criteria which translates the NICE recommendation into a clinical guide as to use in practice. These treatment criteria can be found on the application form(s) on the Blueteq site.

NHS England will then routinely commission iptacopan in patients with PNH via commissioned centres.

NICE TA1000: Iptacopan for treating paroxysmal nocturnal haemoglobinuria

Ravulizumab Ultomiris^®

Formulary

Concentrate for solution for infusion 300mg/3mL, 1,100mg/11mL, 300mg/30mL

Tertiary centres only

NICE TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria

NICE TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome

Voxelotor

Formulary

NICE TA981: Voxelotor for treating haemolytic anaemia caused by sickle cell disease

Rituximab

Formulary

Off-label use for the treatment of autoimmune haemolytic anaemia in adults (AIHA)

Rituximab is recommended as an alternative treatment for adults with AIHA where patients are contraindicated to or fail to respond to standard active treatments (e.g corticosteroids).

Treatment requires initiation and continuation by specilist haematology services.

Links